



Forbion Co-Leads €17.4m Oversubscribed Series A Financing of Novameat to accelerate and scale production capacity of plant-based meat

- *Oversubscribed financing round co-led by Forbion's BioEconomy fund strategy, which focusses on biotech companies that address planetary health challenges, together with Sofinnova Partners and existing investors*
- *Funding will enable Novameat to scale production capacity through its proprietary MicroForce technology*
- *Alex Hoffmann, General Partner at Forbion to join Novameat Board of Directors with Joy Faucher, Partner at Forbion appointed as Board Observer*

Naarden, The Netherlands, 10 September, 2024 -- Forbion, a leading global life sciences venture capital firm with deep expertise in Europe, today announced it has co-led a €17.4m Series A Financing of Novameat, a sustainable food technology company creating pioneering plant-based products with a unique fibrous texture and strong customer acceptance. The financing was co-led by Forbion via its BioEconomy fund strategy and Sofinnova Partners, with participation from existing investors Unovis Asset Management, Praesidium and Rubio Impact Ventures. Alex Hoffmann, General Partner of Forbion's BioEconomy fund strategy, will join the company's board of directors. This round of funding will enable Novameat to scale production capacity using its proprietary MicroForce technology, expand its product offerings, and enhance its market presence globally.

This round of funding will be used to increase commercial activities in new regions with an expanded product portfolio, including Novameat's the new Shredded Nova-b*ef, officially being launched on the 16th of September. The capital will also be used to further scale production and accelerate research and development efforts, enabling the company to continue leading in the field of sustainable, high-protein products.

Alex Hoffmann, General Partner at Forbion for its BioEconomy Fund noted, "Novameat's proprietary technology is truly groundbreaking. We see significant potential, not only in their current products, but also in the pipeline of innovations they are developing. We are excited to work with the Novameat team as they continue to push the boundaries in plant-based foods and contribute to solving critical planetary sustainability issues."

"We are delighted to close this Series A round and are grateful for the confidence shown by our new partners and the continued support of our existing investors", **said Giuseppe Scianti, CEO and Founder of Novameat.** "This funding marks a significant milestone in our journey and we are more committed than ever to empower people to prioritise their

wellbeing and our planet. It's great that this coincides with the launch of our new Shredded Nova-b*ef, which has received incredibly positive feedback in the market."

Since its inception, Novameat has brought several innovative products to market across Europe, industrially scaled its proprietary MicroForce technology, which creates the signature texture, and modified the production facility to meet stringent BRCGS (Brand Reputation Compliance Global Standard) requirements. The company's unique B2B approach and technological scalability has attracted the attention of large foodservice customers and industry players, positioning it as a leader in the future of the plant-based proteins, in a market that is increasingly looking for healthier and more exciting options.

*****ENDS*****

For more information, please contact:

Forbion Investor Relations

Email: Robbert.van.de.Griendt@forbion.com

General Partner IR & Impact

Forbion Communications

Email: laura.asbjornsen@forbion.com

Head of Communications

About Forbion

Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, The Netherlands, Munich, Germany and Boston, USA. Forbion invests in innovative biotech companies, managing €3.2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address 'planetary health' challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies. Forbion's team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with investments in over 110 companies across 9 funds. Forbion's record of sourcing, building and guiding life sciences companies has resulted in many approved breakthrough therapies and valuable exits. Forbion typically selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.

About Novameat

Novameat leads the way in creating sustainable plant-based meats with a unique fibrous texture. Their dedicated team of innovators combines advanced food science with culinary expertise to develop its proprietary texturising technology, delivering products with an

original taste and texture, and a satisfying bite. By prioritising nourishing, high-quality ingredients and avoiding common allergens and complex additives, the company provides an inclusive protein source that everyone can enjoy.

Founded in 2018 in Barcelona and led by founder Dr. Giuseppe Scionti, inventor of the world's first 3D printed plant-based steak, the company has since then developed the proprietary texturizing MicroForce technology, which scales the principles of 3D printing at industrial level. For more information, please visit: www.novameat.com.